Cardiac fibroblasts: Active players in (atrial) electrophysiology?; [Kardiale Fibroblasten: Aktive Mitspieler in der (atrialen) Elektrophysiologie?]

被引:24
作者
Klesen A. [1 ,2 ]
Jakob D. [1 ,2 ]
Emig R. [1 ,2 ]
Kohl P. [1 ,2 ]
Ravens U. [1 ,2 ]
Peyronnet R. [1 ,2 ]
机构
[1] Institute for Experimental Cardiovascular Medicine, University Heart Center, Medical Center—University of Freiburg, Elsässer Str. 2q, Freiburg i. Br.
[2] Faculty of Medicine, University of Freiburg, Freiburg
关键词
Atrial fibrillation; Atrial Fibroblasts; Cardiomyocytes; Electrophysiological phenomena; Myofibroblasts;
D O I
10.1007/s00399-018-0553-3
中图分类号
学科分类号
摘要
Fibrotic areas in cardiac muscle—be it in ventricular or atrial tissue—are considered as obstacles for conduction of the excitatory wave and can therefore facilitate re-entry, which may contribute to the sustenance of cardiac arrhythmias. Persistence of one of the most frequent arrhythmias, atrial fibrillation (AF), is accompanied by enhanced atrial fibrosis. Any kind of myocardial perturbation, whether via mechanical stress or ischemic damage, inflammation, or irregular and high-frequency electrical activity, activates fibroblasts. This leads to the secretion of paracrine factors and extracellular matrix proteins, especially collagen, and to the differentiation of fibroblasts into myofibroblasts. Excessive collagen production is the hallmark of fibrosis and impairs regular impulse propagation. In addition, direct electrical coupling between cardiomyocytes and nonmyocytes, such as fibroblasts and macrophages, via gap junctions affects conduction. Although fibroblasts are not electrically excitable, they express functional ion channels, in particular K+ channels and mechanosensitive channels, some of which could be involved in tissue remodeling. Here, we briefly review these aspects with special reference to AF. © 2018, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
引用
收藏
页码:62 / 69
页数:7
相关论文
共 61 条
[1]  
Souders C.A., Bowers S.L., Baudino T.A., Cardiac fibroblast: the renaissance cell, Circ Res, 105, pp. 1164-1176, (2009)
[2]  
Pinto A.R., Ilinykh A., Ivey M.J., Kuwabara J.T., D'Antoni M.L., Debuque R., Chandran A., Wang L., Arora K., Rosenthal N.A., Tallquist M.D., Revisiting cardiac cellular composition, Circ Res, 118, pp. 400-409, (2016)
[3]  
Tallquist M.D., Molkentin J.D., Redefining the identity of cardiac fibroblasts, Nat Rev Cardiol, 14, pp. 484-491, (2017)
[4]  
Gourdie R.G., Dimmeler S., Kohl P., Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease, Nat Rev Drug Discov, 15, pp. 620-638, (2016)
[5]  
Krenning G., Zeisberg E.M., Kalluri R., The origin of fibroblasts and mechanism of cardiac fibrosis, J Cell Physiol, 225, pp. 631-637, (2010)
[6]  
Kohl P., Gourdie R.G., Fibroblast-myocyte electrotonic coupling: does it occur in native cardiac tissue?, J Mol Cell Cardiol, 70, pp. 37-46, (2014)
[7]  
Ongstad E., Kohl P., Fibroblast-myocyte coupling in the heart: potential relevance for therapeutic interventions, J Mol Cell Cardiol, 91, pp. 238-246, (2016)
[8]  
Manabe I., Shindo T., Nagai R., Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy, Circ Res, 91, pp. 1103-1113, (2002)
[9]  
Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., West A.B., Myofibroblasts. I. Paracrine cells important in health and disease, Am J Physiol, 277, pp. C1-C9, (1999)
[10]  
Brown R.D., Ambler S.K., Mitchell M.D., Long C.S., The cardiac fibroblast: therapeutic target in myocardial remodeling and failure, Annu Rev Pharmacol Toxicol, 45, pp. 657-687, (2005)